Payment overview · 2025
General Payments
$332.81
17 reported records · 13 companies
Healthcare provider profile · identity verified
William Andrew White, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STATESVILLE, NC · NPI 1194704981
Verified facts
What the public records show
CMS Open Payments records show William Andrew White, MD received $332.81 in general payments during 2025 across 17 reported records.
Lilly USA, LLC accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Paxlovid, Rexulti, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.54 | 15.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.05 | 15.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.78 | 11.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.52 | 8.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.73 | 7.7% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.51 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.93 | 6.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.24 | 5.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.13 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.19 | 4.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.50 | 4.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.47 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.22 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $332.81 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.54 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $26.52 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| MOLLI Normalized: molli |
Device | Stryker Corporation | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 53 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
53 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 806 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 633 | 145 |
| Lisinopril | Lisinopril | 584 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 578 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 533 | 119 |
| Escitalopram Oxalate | Escitalopram Oxalate | 521 | 99 |
| Simvastatin | Simvastatin | 364 | 84 |
| Trazodone Hcl | Trazodone Hcl | 297 | 51 |
| Gabapentin | Gabapentin | 295 | 57 |
| Metformin Hcl Er | Metformin Hcl | 252 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 60 |
| Donepezil Hcl | Donepezil Hcl | 236 | 55 |
| Omeprazole | Omeprazole | 231 | 56 |
| Furosemide | Furosemide | 226 | 62 |
| Tramadol Hcl | Tramadol Hcl | 218 | 58 |
| Cefdinir | Cefdinir | 214 | 164 |
| Meloxicam | Meloxicam | 212 | 59 |
| Alprazolam | Alprazolam | 209 | 36 |
| Carvedilol | Carvedilol | 207 | 40 |
| Potassium Chloride | Potassium Chloride | 192 | 42 |
| Losartan Potassium | Losartan Potassium | 188 | 48 |
| Sertraline Hcl | Sertraline Hcl | 183 | 43 |
| Allopurinol | Allopurinol | 175 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 36 |
| Mirtazapine | Mirtazapine | 161 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 160 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 40 |
| Ezetimibe | Ezetimibe | 152 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 149 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 36 |
| Alendronate Sodium | Alendronate Sodium | 136 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 28 |
| Prednisone | Prednisone | 128 | 102 |
| Glimepiride | Glimepiride | 124 | 29 |
| Montelukast Sodium | Montelukast Sodium | 124 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 22 |
| Eliquis | Apixaban | 110 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 62 |
| Memantine Hcl Er | Memantine Hcl | 87 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 15 |
| Metformin Hcl | Metformin Hcl | 72 | 20 |
| Januvia | Sitagliptin Phosphate | 68 | suppressed |
| Famotidine | Famotidine | 66 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 15 |
| Jardiance | Empagliflozin | 62 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 25 |
| Solifenacin Succinate | Solifenacin Succinate | 60 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 14 |
| Synthroid | Levothyroxine Sodium | 58 | suppressed |
| Ozempic | Semaglutide | 57 | 17 |
| Bupropion Xl | Bupropion Hcl | 56 | 12 |
| Azithromycin | Azithromycin | 55 | 47 |
| Paxlovid | Nirmatrelvir/Ritonavir | 53 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Spironolactone | Spironolactone | 52 | 12 |
| Benazepril Hcl | Benazepril Hcl | 51 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 11 |
| Atenolol | Atenolol | 46 | 11 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Celecoxib | Celecoxib | 44 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | 12 |
| Finasteride | Finasteride | 42 | 12 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Indapamide | Indapamide | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 24 |
| Fluconazole | Fluconazole | 34 | 19 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 20 |
| Torsemide | Torsemide | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 21 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $332.81 · 17 records | Lilly USA, LLC | AIRSUPRA, Cologuard Collection Kit, EVENITY, JARDIANCE, Leqembi, MOLLI, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, PROLIA, REXULTI, Rybelsus, TRINTELLIX, VOQUEZNA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error